×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENTA – enanta pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/26
04:51 am
enta
Antibiotic Resistance Therapeutics Market Research Report 2025-2029 - Search for Alternatives to Antibiotics Creates New Global Goldrush [Yahoo! Finance]
Low
Report
Antibiotic Resistance Therapeutics Market Research Report 2025-2029 - Search for Alternatives to Antibiotics Creates New Global Goldrush [Yahoo! Finance]
12/24
08:14 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.
12/24
07:00 am
enta
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
Neutral
Report
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
12/23
11:16 am
enta
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? [Yahoo! Finance]
12/9
06:30 am
enta
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Low
Report
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
12/6
05:02 pm
enta
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) [Yahoo! Finance]
High
Report
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) [Yahoo! Finance]
12/6
05:00 pm
enta
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
High
Report
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
11/29
01:00 am
enta
Enanta Pharmaceuticals' Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals' Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/25/2024
04:01 pm
ENTA
enanta pharmaceuticals, inc.
MISS
Report
-5.0%
enanta pharmaceuticals, inc.
11/25/2024
04:01 pm
ENTA
enanta pharmaceuticals, inc.
MISS
Report
2.3%
enanta pharmaceuticals, inc.
11/25/2024
04:01 pm
ENTA
enanta pharmaceuticals, inc.
MISS
Report
5.8%
enanta pharmaceuticals, inc.
11/25/2024
04:01 pm
ENTA
enanta pharmaceuticals, inc.
MISS
Report
5.1%
enanta pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
11/26
08:00 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-4.0%
11/26
08:00 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-4.0%
11/26
07:50 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-4.0%
11/26
07:50 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-4.0%
Date
Time
Symbol
Headline
Impact
12/10
05:12 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Kieffer Tara Lynn
High
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Kieffer Tara Lynn
12/10
05:09 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Luu Brendan
High
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Luu Brendan
12/10
05:04 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Rottinghaus Scott T.
High
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Rottinghaus Scott T.
12/10
05:01 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Or Yat Sun
High
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Or Yat Sun
12/10
04:58 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: MELLETT PAUL J
High
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: MELLETT PAUL J
12/10
04:55 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Luly Jay R.
High
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 06 Filed by: Luly Jay R.
12/9
08:30 am
enta
Form 8-K ENANTA PHARMACEUTICALS For: Dec 09
Medium
Report
Form 8-K ENANTA PHARMACEUTICALS For: Dec 09
12/3
06:41 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luu Brendan
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luu Brendan
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Baird likes Enanta's potential in COVID-19, upgrades to Outperform [Seeking Alpha]
11.2%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
TOP News Decliners
3/14
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
-24.0%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: